Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]
News [3696]
Articles [22]
Editorials [1]
Conferences [136]
elearning [0]
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
CAR-T cell therapy CTL019 recommended for approval by FDA advisory committee to treat paediatric, young adult r/r B-cell ALL
CAR-T cell therapy CTL019 recommended for approval by FDA advisory committee to treat paediatric, young adult r/r...
How a few drops of blood led to a breakthrough in immunology
How a few drops of blood led to a breakthrough in immunology
Last Month in Oncology with Dr. Bishal Gyawali: June 2017
Last Month in Oncology with Dr. Bishal Gyawali: June 2017
AML: Two distinct patterns of stem cells explain relapse
AML: Two distinct patterns of stem cells explain relapse
CTL019 in adult patients with relapsed or refractory diffuse large B-cell Lymphoma
CTL019 in adult patients with relapsed or refractory diffuse large B-cell Lymphoma
The more the T-lymphocytes differ, the more effectively they fight against leukaemia
The more the T-lymphocytes differ, the more effectively they fight against leukaemia
Existing drugs could benefit patients with bone cancer, genetic study suggests
Existing drugs could benefit patients with bone cancer, genetic study suggests
Localised signalling islands in cells may be new targets for precision drug design
Localised signalling islands in cells may be new targets for precision drug design
Gilteritinib, a FLT3 inhibitor, shows promise in relapsed leukaemia
Gilteritinib, a FLT3 inhibitor, shows promise in relapsed leukaemia

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation